Apoteket AB

GOTHENBURG, SWEDEN / ACCESSWIRE / February 20, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 13, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that its CEO Richard Godfrey is leaving his position and that the Board of directors has appointed Gunnar Olsson as Interim CEO. Gunnar Olsson is currently Chairman of the Board of IRLAB but will now transition to a position as a Board director. The Board of directors has appointed the company's current Vice Chairman, Carola Lemne, as its new Chairman. All changes will be implemented immediately and the process to recruit a permanent CEO will start immediately. "The Board has reached the conclusion that a change of CEO is in the best interest of the company. I would like to take this opportunity to thank Richard for his contributions and wish him every success in the future. With strong support from IRLAB's management team and other employees, I will now lead the company until a permanent CEO is in place," says IRLAB's Chairman of the Board and incoming Interim CEO, Gunnar Olsson. "I look forward to leading the work of the Board during the exciting time ahead for IRLAB. We are in the midst of an in-depth analysis of all the data generated in the Phase 2b study of mesdopetam, and later this year the drug candidate IRL757 is expected to be ready for a Phase 1 clinical trial. In the first half of 2024, we expect to both present the results from the Phase 2b study of pirepemat and initiate the first clinical study of yet another of our drug candidates, IRL942. Furthermore, we have now started the development of an entirely new class of Parkinson's drugs, with drug candidate IRL1117 at the forefront," says Carola Lemne, incoming Chairman of the Board of IRLAB. Gunnar Olsson (b. 1953) was elected to IRLAB's Board of Directors in 2017 and has been Chairman of the Board since 2020. He is a licensed physician, holds a Ph.D., and is a specialist in cardiology and internal medicine. Between 1998 and 2010, he was an adjunct professor at the Department of Medicine at Karolinska Institutet. Gunnar Olsson is also an honorary Doctor of Medicine at the University of Gothenburg. He has more than 30 years of experience in leading positions in the life science industry. He has been Vice President & Head of Cardiovascular and Gastrointestinal Therapy Areas in Global R&D at AstraZeneca and has served on several boards of biotech companies and the European Society of Cardiology. Details of current board assignments are available on the company's website. Carola Lemne (b. 1958) was elected to IRLAB's Board of Directors in 2018 and is the company's Vice Chairman. She is a licensed physician, Doctor of Medicine and associate professor, and has a background as CEO of the Confederation of Swedish Enterprise and Danderyd University Hospital as well as CEO of Praktikertjänst AB, clinical research manager and head of global strategic drug development and regulatory strategy at Pharmacia Corp. She has held board positions in Getinge, Apoteket, Alecta, MEDA, Investor and AFA Försäkringar and has also been a board member of, among others, the Foundation for Strategic Research, the State Delegation for Clinical Research, the Research Institute of Industrial Economics and the Swedish Corporate Governance Board, as well as Chair of Uppsala University. Details of current board assignments are available on the company's website. For more information Gunnar Olsson, interim CEO Phone: +46 70 576 14 02 E-mail: gunnar.olsson@irlab.se Viktor Siewertz, CFO Phone: +46 727 10 70 70 E-mail: viktor.siewertz@irlab.se This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-20 17:45 CET. About IRLAB IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam. IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on . Attachments IRLAB changes CEO and appoints new Chairman SOURCE: IRLAB Therapeutics View source version on accesswire.com:

STOCKHOLM, SWEDEN / ACCESSWIRE / August 26, 2022 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) - presents today, August 26, its report for the second quarter. Summary of financial performance Net sales for the quarter amounted to SEK 84 (12) thousand. The quarter's net sales consist of revenues related to the sale of the Dosell digital pharmaceutical robot. Operating profit for the quarter amounted to SEK -5,184 (-7,962) thousand. Profit after financial items for the quarter amounted to -5,233 (-8,258) TSEK. Cash flow for the period amounted to SEK -7,155 (-5,400) thousand. Earnings per share for the quarter before / after dilution amounted to SEK -0,1 (-0,2). Equity per share at the end of the period amounted to SEK 0,4 (0,4). The equity/assets ratio at the end of the period was 81.8 (39.5) percent. Significant events in the quarter The company has launched an updated version of Dosell that includes several new improvements and features that enhance both the user experience and reliability. During the month of June, the company has delivered a large batch to Apoteket AB, which has had a high demand for the company's products and has sold out of its stock. Significant events after the end of the quarter iZafe signs a Letter of Intent to acquire Pilloxa AB. Pilloxa has developed a technical platform for improved adherence that pharmaceutical companies use to design digital patient support. The purchase price will be paid in 70,874,308 newly issued iZafe shares with an indicative value of approximately 30 million SEK. COMMENTS FROM THE CEO Our vision is to ensure health through better adherence and in the last quarter we have taken an even bigger step through our updated vision and strategy presented in May. During the second quarter, we focused on consumer advertising, which continues to deliver good results and improved Dosell's performance. At the same time, we are seeing increased interest among municipalities in both pharmaceutical robots and the data they can bring to medication management. After the end of the quarter, we announced a letter of intent to acquire Pilloxa AB. The acquisition of Pilloxa creates a unique position in digital health With the acquisition of Pilloxa, we have the opportunity to create a more comprehensive offering that meets the different needs of consumers, from independent medication management to the choice of a smart connected pillbox or a fully automated medication robot. The acquisition of Pilloxa also gives us access to additional sales channels as we complement each other very well. Pilloxa has had pharmaceutical companies as its primary customer group and has developed a unique SaaS solution as well as support for the conduct of clinical studies. Immediately after the acquisition, we will start the journey towards making Pilloxa's solution more commercially viable in our existing sales channels. Pilloxa's employees and the expertise they bring, are an important part of the acquisition. They come in with the right kind of knowledge and the experience we need to create a company that takes the position of being the leader in the market to ensure adherence to medication and ultimately, to demonstrate the health benefits of it. We are working to optimize our organization to cut costs and prepare for a future merge. The company is continuing discussions with investors, who are keen to see more acquisitions and organic growth in a market that is largely untapped. Following our communication regarding the acquisition of Pilloxa, interest has increased further - which is positive for future funding of the company in addition to the warrant program TO10B which, depending on the stock price, will provide a better capital contribution. B2C - continual increased sales and the potential outside Sweden In recent months, we have invested in television advertising to spread awareness of Dosell. As a result, we now sell around 100 units a month via the Apoteket website and the consumer version of Dosell accounts for around 90% of all dispensations today. This is a very good start for a brand-new type of product and service, but not enough and hence need to find more ways to get higher volumes out. Our investment here in Sweden with the consumer version of Dosell has been crucial in creating the experience and knowledge needed to export the solution to other countries and markets. In all dialogues with potential partners, there has also been interest in our vision's future solutions, which we will now be able to sell and distribute much more quickly in connection with the acquisition of Pilloxa. However, the concept in Italy continues with delays due to production and software changes. The Italian market has great potential where we see great advantages in the customer being able to have their medicines packaged in sachet bags directly by the local pharmacy together with their Dosell. In the Swedish market this is a challenge where we see long lead times to get their medicines in sachet bags if they do not already use it when they have bought their Dosell. Therefore, we see great potential in the Italian concept, which is also applicable to more markets in Europe. B2B - interest in medication data We see a clear trend that more municipalities are starting to demand pharmaceutical robots, with many tenders just coming out in both Sweden and Norway. We have also noticed strong demand from welfare platforms that want to get data on medication. With the acquisition of Pilloxa, this becomes a complete solution for welfare platforms as we can provide even more data around medication adherence. Continuous improvement We are constantly working to improve Dosell's performance. As we communicated in the spring, we had production challenges and a software release that included improvements necessary for our partners to deploy their Dosell in the field. These elements were completed too late into the summer holidays and as a result our partners are now able to go live after the summer months. We have an exciting and intense period ahead of us. Our many partners and customers will start up the use of Dosell, we will finalize all the elements around the acquisition and ensure to develop an attractive joint future offering. Contacts Anders Segerström, Chief Executive Officer E-mail: anders.segerstrom@izafegroup.com Phone number: +46 70-875 14 12 iZafe Group AB (publ.) Södra Fiskartorpsvägen 20 114 33 Stockholm E-mail: ir@izafegroup.com About Us iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm. The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at . This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-26 08:30 CEST. Attachments Q2 Interim Report IZafe Group 2022 SOURCE: iZafe Group View source version on accesswire.com:

STOCKHOLM, April 22, 2021 /PRNewswire/ -- Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding Chairman of the board, Vice Chairman of the board and other board members. The Nomination Committee proposes: that the board shall consist of five ordinary board members, that the board shall consist of five ordinary board members, that Anders Ekblom and Graham Dixon are re-elected as board members, that Hans-Peter Ostler, Eva Sjökvist Saers and Veronica Wallin are elected as new board members, that Hans-Peter Ostler, Eva Sjökvist Saers and Veronica Wallin are elected as new board members, that Anders Ekblom is elected as new Chairman of the board, and that Hans-Peter Ostler is elected as new Vice Chairman of the board. The current board members Peter Benson, Carl Borrebaeck, Ulrika Danielsson, Kirsten Drejer, Kenth Petersson and Jonas Sjögren have declined re-election. Hans-Peter Ostler, born 1971, has many years of experience in investment banking and private banking, including from Danske Bank, and currently works as wealth manager at Söderberg & Partners. Hans-Peter Ostler's previous experiences include assignments such as board member of IRLAB Therapeutics AB. Other ongoing assignments: Chairman of OBLIQUE THERAPEUTICS AB. Board member of S.P. HMSO Göteborg AB. Deputy board member of O Mgmt AB. Education: University studies in economics and law etc. at the School of Business, Economics and Law at Gothenburg University. Shareholding in Alligator Bioscience AB: 110,000 shares. Eva Sjökvist Saers, born 1962, has many years of experience from the pharmaceutical industry where she has worked in various leading positions within Astra/AstraZeneca, Apoteket AB and as CEO of the pharmaceutical company Apotek Produktion & Laboratorier AB (APL) for more than 10 years. Eva Sjökvist Saers is currently involved in a number of boards within life science, including the role as Chairman of the board of Dicot AB. Eva Sjökvist Saers is also Chairman of the strategic innovation area Swelife and has previously been Chairman of Apotekarsocieteten and Vice Chairman of SwedenBIO. Other ongoing assignments: Chairman of the board of Dicot AB. Board member of Bluefish Pharmaceuticals AB (publ), IDL Biotech AB and Oxcia AB. Deputy board member of Brainstorm Aktiebolag. Education: Doctoral degree in pharmaceutical science from Uppsala University. Shareholding in Alligator Bioscience AB: - Veronica Wallin, born 1986, has since 2017 worked as CFO at the medical technology company Episurf Medical AB. Veronica Wallin has previously, among other things, been CFO at the pharmacy company ApoEx AB. Other ongoing assignments: Episurf Europe AB, Episurf IP-Management AB and Episurf Operations AB. Education: Master of Science in Business and Economics from Stockholm University. Shareholding in Alligator Bioscience AB: - The Nomination Committee's other proposals and reasoned statement will be presented in connection with the announcement of the notice to the annual general meeting 2021. The Nomination Committee for the 2021 annual general meeting consists of: Lars Bergkvist (Chairman), representing Lars Spånberg, Lars Bergkvist (Chairman), representing Lars Spånberg, Hans-Peter Ostler, representing Jonas Sjögren, Jan Lundström, representing Sunstone Life Science Ventures II K/S, and Peter Benson, Chairman of the board. For further information, please contact: Lars Bergkvist, Chairman of the Nomination Committee Phone: +46 70 601 06 70 E-mail: lars.bergkvist60@gmail.com This information is information that Alligator Bioscience AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7.30 pm CEST on April 22, 2021. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit . This information was brought to you by Cision The following files are available for download: Company Codes: Bloomberg:ATORX@SS, ISIN:SE0000767188, RICS:ATORX.ST, Stockholm:ATORX